BMO Capital Reiterates Market Perform Rating on Gilead Sciences (GILD)

BMO Capital analyst Evan David Seigerman reiterated a Market Perform rating and $63.00 price target on Gilead Sciences (NASDAQ: GILD), following AstraZeneca's presentation on DESTINY-Breast04 results.

The analyst comments: "Late-breaking data from the DESTINY-Breast04 trial of Enhertu complicates positioning of Trodelvy in HR+/HER2- breast cancer patients. Following yesterday's presentation of TROPiCS-02 with a modest PFS benefit, data from the DESTINY-Breast 04 trial may make any positive trends we saw with Trodelvy in HR+/HER2- BC far less relevant in the real world treatment of patients. We saw impressive OS benefit in the HR and HR- groups, where we can likely assume that ~60% of HER2-low are HER2-. Per the presentation: “We anticipate these results to be practice-changing.”"

For an analyst ratings summary and ratings history on Gilead Sciences click here. For more ratings news on Gilead Sciences click here.

Shares of Gilead Sciences closed at $63.45 yesterday.

By Vlad Schepkov

You May Also Be Interested In

• Gilead Sciences (GILD) Misses Q1 EPS by 288c
• Acrivon Therapeutics Inc (ACRV) PT Lowered to $22 at Jones Trading
• Gilead posts quarterly loss on acquisition charge, revenue rises 5%